Abstract
In Thailand, access to atorvastatin is largely limited to patients with previous cardiovascular (CV) events given its inclusion in the Thai reimbursement list for secondary prevention. This study aims to estimate the short-term cost-effectiveness (CE) of atorvastatin compared to simvastatin in prevention of CV events in both primary and secondary prevention settings from the societal perspective in Thailand.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
